A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor α chains

被引:44
|
作者
England, BP
Balasubramanian, P
Uings, I
Bethell, S
Chen, MJ
Schatz, PJ
Yin, Q
Chen, YF
Whitehorn, EA
Tsavaler, A
Martens, CL
Barrett, RW
McKinnon, M
机构
[1] Affymax Res Inst, Palo Alto, CA 94304 USA
[2] Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Cell Biol Unit, Stevenage SG1 2NY, Herts, England
[3] Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Prot Sci Unit, Stevenage SG1 2NY, Herts, England
关键词
D O I
10.1073/pnas.110053997
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Two series of peptides that specifically bind to the extracellular domain of the alpha chain of the human interleukin-5 receptor (IL-5R alpha). but share no primary sequence homology to IL-5, were identified from libraries of random recombinant peptides. Affinity maturation procedures generated a 19-aa peptide that binds to the IL-5 receptor alpha/beta heterodimer complex with an affinity equal to that of IL-5 and is a potent and specific antagonist of IL-5 activity in a human eosinophil adhesion assay. The active form of the peptide is a disulfide-crosslinked dimer that forms spontaneously in solution. Gel filtration analysis, receptor-binding studies, and analytical ultracentrifugation reveal that the dimeric peptide binds simultaneously to two receptor alpha chains in solution. Furthermore, the dimer peptide, but not IL-5, can activate a chimeric receptor consisting of the IL-5R alpha extracellular domain fused to the intracellular domain of the epidermal growth factor receptor, thus demonstrating that the peptide also promotes receptor dimerization in a cellular context. The functional antagonism produced by the bivalent interaction of the dimeric peptide with two IL-5R alpha chains represents a distinctive mechanism for the antagonism of cytokines that use heteromeric receptors.
引用
收藏
页码:6862 / 6867
页数:6
相关论文
共 50 条
  • [1] Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor
    Morokata, T
    Ida, K
    Yamada, T
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2002, 2 (12) : 1693 - 1702
  • [2] INTERLEUKIN-5
    TAKATSU, K
    CURRENT OPINION IN IMMUNOLOGY, 1992, 4 (03) : 299 - 306
  • [3] INTERLEUKIN-5
    BANCHEREAU, J
    M S-MEDECINE SCIENCES, 1990, 6 (10): : 954 - 957
  • [4] INTERLEUKIN-5
    MCKENZIE, ANJ
    SANDERSON, CJ
    ADVANCES IN NEUROIMMUNOLOGY, 1992, 2 (01): : 67 - 79
  • [5] INTERLEUKIN-5
    MCKENZIE, ANJ
    SANDERSON, CJ
    CHEMICAL IMMUNOLOGY, 1992, 51 : 135 - 152
  • [6] Functional analysis of the interleukin-5 receptor antagonist peptide, AF18748
    Rosas, M
    Uings, IJ
    van Aalst, C
    Lammers, JWJ
    Koenderman, L
    Coffer, PJ
    CYTOKINE, 2004, 26 (06) : 247 - 254
  • [7] COVALENT MODIFICATION OF THE INTERLEUKIN-5 RECEPTOR BY ISOTHIAZOLONES LEADS TO INHIBITION OF THE BINDING OF INTERLEUKIN-5
    DEVOS, R
    GUISEZ, Y
    PLAETINCK, G
    CORNELIS, S
    TAVERNIER, J
    VANDERHEYDEN, J
    FOLEY, LH
    SCHEFFLER, JE
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 225 (02): : 635 - 640
  • [8] Receptor epitope usage by an interleukin-5 mimetic peptide
    Ishino, T
    Urbina, C
    Bhattacharya, M
    Panarello, D
    Chaiken, I
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (24) : 22951 - 22961
  • [9] THE BIOLOGY OF INTERLEUKIN-5 AND ITS RECEPTOR
    MAHANTY, S
    NUTMAN, TB
    CANCER INVESTIGATION, 1993, 11 (05) : 624 - 634
  • [10] INTERLEUKIN-5 (IL-5) AND ITS RECEPTOR
    TAKATSU, K
    MICROBIOLOGY AND IMMUNOLOGY, 1991, 35 (08) : 593 - 606